Shaheen, Collins Lead 243 Lawmakers in Pushing for Reauthorization of Special Diabetes Program
(Washington, DC) – U.S. Senators Jeanne Shaheen (D-NH) and Susan Collins (R-ME), co-chairs of the U.S. Senate Diabetes Caucus and leaders of the bipartisan INSULIN Act to cap monthly out-of-pocket insulin costs at $35, are leading 56 of their Senate colleagues and 185 U.S. Representatives in a bipartisan letter to Senate and House leadership emphasizing the importance of the Special Diabetes Program (SDP) and the Special Diabetes Program for Indians (SDPI). They were joined in this effort by House Diabetes Caucus Co-chairs Diana DeGette (D-CO-1) and Gus Bilirakis (R-FL-12). Earlier this year, Shaheen and Collins secured a short-term reauthorization of SDP funding at a rate of approximately $200 million per year as part of the Fiscal Year 2026 funding packages—the highest level in the program’s nearly 30-year history. Without further action in Congress, however, authorization for the SDP will expire on December 31, 2026.
The lawmakers wrote, in part: “Diabetes is one of our country’s most expensive diseases in both human and economic terms, affecting people of all ages and races, and in every region of our country [...] Although the costs and prevalence of diabetes continue to increase, the SDP is making meaningful progress. The SDP comprises two partner components: the Special Statutory Funding Program for Type 1 Diabetes Research (SDP) and the Special Diabetes Program for Indians (SDPI). Since the program’s inception, both components have delivered critical resources and research breakthroughs for the more than 40 million Americans with diabetes and 115.2 million with prediabetes, as well as their loved ones.”
They continued: “Research funded by the program is leading to new insights and treatment options that improve the lives of diabetes patients and accelerate progress toward curing and preventing the disease [...] According to a 2025 study, advances supported by SDP-funded research have generated an estimated $50 billion in federal healthcare cost savings through improved diabetes management. Long-term, sustained investment in this program would provide the stability researchers need to continue large-scale trials, conduct outreach and education, and determine where best to allocate resources – all of which play an important role in helping to better treat, prevent, and ultimately cure diabetes.”
They concluded: “Congress has reauthorized these programs with bipartisan support on a regular basis since the programs’ inception in 1997. The researchers and clinicians who deliver the programs’ benefits require stable, predictable funding to maximize their contributions to the diabetes community [...] A multi-year extension of SDP beyond December 2026 will continue the program’s momentum and provide renewed hope for the diabetes community. We urge you to support a multi-year extension of SDP and SDPI.”
The full letter can be read HERE.
In addition to Senators Collins and Shaheen, the letter was signed by Senators Angela Alsobrooks (D-MD), Tammy Baldwin (D-WI), Michael Bennet (D-CO), Richard Blumenthal (D-CT), Lisa Blunt Rochester (D-DE), Cory Booker (D-NJ), Maria Cantwell (D-WA), Shelley Moore Capito (R-WV), Chris Coons (D-DE), Catherine Cortez Masto (D-NV), Kevin Cramer (R-ND), Mike Crapo (R-ID), Steve Daines (R-MT), Tammy Duckworth (D-IL), Joni Ernst (R-IA), Deb Fischer (R-NE), Ruben Gallego (D-AZ), Kirsten Gillibrand (D-NY), Chuck Grassley (R-IA), Maggie Hassan (D-NH), Martin Heinrich (D-NM), John Hickenlooper (D-CO), Mazie Hirono (D-HI), John Hoeven (R-ND), Cindy Hyde-Smith (R-MS), Mark Kelly (D-AZ), Andy Kim (D-NJ), Angus King (I-ME), Amy Klobuchar (D-MN), Ben Ray Luján (D-NM), Cynthia Lummis (R-WY), Ed Markey (D-MA), Jeff Merkley (D-OR), Jerry Moran (R-KS), Lisa Murkowski (R-AK), Patty Murray (D-WA), Alex Padilla (D-CA), Gary Peters (D-MI), Jack Reed (D-RI), Jim Risch (R-ID), Jacky Rosen (D-NV), Mike Rounds (R-SD), Brian Schatz (D-HI), Adam Schiff (D-CA), Elissa Slotkin (D-MI), Tina Smith (D-MN), Dan Sullivan (R-AK), Thom Tillis (R-NC), Chris Van Hollen (D-MD), Mark Warner (D-VA), Raphael Warnock (D-GA), Elizabeth Warren (D-MA), Roger Wicker (R-MS), Peter Welch (D-VT), Ron Wyden (D-OR) and Todd Young (R-IN).
As co-chairs of the U.S. Senate Diabetes Caucus, Shaheen and Collins have championed bipartisan efforts to lower insulin costs, expand access to treatment and advance critical diabetes research. The Senators have consistently worked to hold insulin manufacturers, insurers and pharmacy benefit managers accountable for the high costs of life-saving insulin, including through their landmark, bipartisan Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act. The INSULIN Act, which would cap monthly out-of-pocket insulin costs at $35, is closer than ever before to passing out of the U.S. Senate after advancing out of the U.S. Senate Health, Education, Labor and Pensions (HELP) Committee earlier this year.
The Senators also lead the bicameral, bipartisan Strengthening Collective Resources for Encouraging Education Needed (SCREEN) for Type 1 Diabetes Act to improve early detection and screening for Type 1 diabetes and the bipartisan Diabetes Interventions Addressing Barriers to Enrollment, Technology and Education Services (DIABETES) Act to ensure care for diabetic patients is not interrupted when they enroll in Medicare.
###